SEC Company Response from CardioVascular BioTherapeutics, Inc. (CIK 0001303497) — Feb 9, 2005
CardioVascular BioTherapeutics, Inc. (CIK 0001303497)
Date: Feb. 9, 2005 · CIK: 0001303497 · Accession: 0001193125-05-023527
AI Filing Summary & Sentiment
File numbers found in text: 333-119199
Show Raw Text
CORRESP 1 filename1.htm SEC Response Letter February 9, 2005 Securities and Exchange Commission Division of Corporation Finance Judiciary Plaza 450 Fifth Street, N.W. Washington, D.C. 20549 Attention: Greg Belliston Re: CardioVascular BioTherapeutics, Inc. Registration Statement on Form S-1 File No. 333-119199 Dear Mr. Belliston: With respect to the above-referenced Registration Statement on Form S-1 (the “Registration Statement”), the following information regarding the distribution of the prospectus dated September 23, 2004, prospectuses dated January 13, 2005 and the prospectus dated February 4, 2005 is hereby furnished to the Commission pursuant to Rule 460 of the Rules and Regulations of the Commission under the Securities Act of 1933, as amended, in connection with the request for acceleration of the effective date of the Registration Statement. The number of prospectuses dated September 23, 2004, prospectuses dated January 13, 2005 and the prospectuses dated February 4, 2005 as distributed between September 23, 2004 and February 8, 2005 is as follows: No. of copies dated September 23, 2004 No. of copies dated January 13, 2005 No. of copies dated February 4, 2005 To Prospective Underwriters and Dealers: 2,184 2,184 2,184 To Institutions: 107 107 107 To Individuals: 413 413 422 Total: 2,704 2,704 2,713 Sincerely, FIRST DUNBAR SECURITIES CORPORATION As Representative /s/ Robert L. Clark Robert L. Clark Chief Executive Officer